Background: Approximately 6.2% of women in the USA and 3.7% of women in the UK, use Selective Serotonin Reuptake Inhibitors (SSRIs) during their pregnancies because of depression and/or anxiety. In the Netherlands, this prevalence is around 2%. Nonetheless, SSRI use during pregnancy is still controversial. On the one hand SSRIs may be toxic to the intrauterine developing child, while on the other hand relapse or recurrence of depression during pregnancy poses risks for both mother and child. Among patients and professionals there is an urgent need for evidence from randomized studies to make rational decisions regarding continuation or tapering of SSRIs during pregnancy. At present, no such studies exist. Methods/Design: 'Stop or Go' is a pragmatic multicentre randomized non-inferiority trial among 200 pregnant women with a gestational age of less than 16weeks who use SSRIs without clinically relevant depressive symptoms. Women allocated to the intervention group will receive preventive cognitive therapy with gradual, guided discontinuation of SSRIs under medical management (STOP). Women in the control group will continue the use of SSRIs (GO). Primary outcome will be the (cumulative) incidence of relapse or recurrence of maternal depressive disorder (as assessed by the Structured Clinical Interview for DSM disorders) during pregnancy and up to three months postpartum. Secondary outcomes will be child outcome (neonatal outcomes and psychomotor and behavioural outcomes up to 24months postpartum), and health-care costs. Total study duration for participants will be therefore be 30months. We specified a non-inferiority margin of 15% difference in relapse risk. Discussion: This study is the first to investigate the effect of guided tapering of SSRIs with preventive cognitive therapy from early pregnancy onwards as compared to continuation of SSRIs during pregnancy. We will study the effects on both mother and child with a pragmatic approach. Additionally, the study examines cost effectiveness. If non-inferiority of preventive cognitive therapy with guided tapering of SSRIs compared to intended continuation of SSRIs is demonstrated for the primary outcome, this may be the preferential strategy during pregnancy. Trial registration: Netherlands Trial Register (NTR): NTR4694 ; registration date: 16-jul-2014

Antidepressants, Cognitive therapy, Cost-effectiveness, Depression, Perinatal outcome, Pregnancy, Prevention, Recurrence, Relapse, Selective serotonin reuptake inhibitors, SSRI
dx.doi.org/10.1186/s12888-016-0752-6, hdl.handle.net/1765/81894
BMC Psychiatry
Department of Gynaecology & Obstetrics

Molenaar, N.M, Brouwer, M, Bockting, C.L.H, Bonsel, G.J, van der Veere, C.N, Torij, H.W, … Lambregtse-van den Berg, M.P. (2016). Stop or go? Preventive cognitive therapy with guided tapering of antidepressants during pregnancy: Study protocol of a pragmatic multicentre non-inferiority randomized controlled trial. BMC Psychiatry, 16(1). doi:10.1186/s12888-016-0752-6